The study, funded by a $3.3 million grant from the National Institutes of Health, will allow researchers to use the latest in imaging techniques and tissue analysis to develop personalized treatment pathways for bicuspid aortic valve patients. The condition affects more than 7 million people in North America.
The study will include a group of 450 patients.
“Not all BAV patients are the same, yet they are currently treated the same when it comes to timing and extent of surgery,” said Dr. Paul Fedak, professor in University of Calgary medical school’s cardiac sciences and surgery departments as well as a member of the Libin Cardiovascular Institute of Alberta. “Through this study we can give clinicians and surgeons the tools they need to create precise, individualized treatment plans for patients.”
More articles on health IT:
Microsoft to use AI in antivirus software
Apple, Cisco may offer customers cybersecurity insurance discounts
21 hospitals, health systems seeking Cerner, Meditech, Epic talent
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
